CCT4

Across TCGA pan-cancer cohorts, CCT4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CCT4 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CCT4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CCT4 expression acts as an unfavorable survival marker, although some lineages such as LSCC and COAD show a favorable association.

LUAD, LSCC, and COAD are the cancer types where CCT4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.313	0.924	<.001	31	view →
LSCC	DFS	Quartile	II,III,IV	0.774	0.371	.007	11	view →
COAD	DFS	Median	III,IV	1.000	0.846	.049	6	view →
CCRCC	DFS	Tertile	All	0.631	0.860	.021	6	view →
PDAC	DFS	Median	III,IV	0.477	0.805	.039	1	view →
HNSC	OS	Median	III,IV	1.000	0.948	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CCT4–LUAD (OS)

Open the LUAD breakdown →